Stanford Hematology Division (@stanfordheme) 's Twitter Profile
Stanford Hematology Division

@stanfordheme

The official account of @StanfordMed's Division of Hematology

ID: 1660707063876706304

linkhttps://med.stanford.edu/hematology calendar_today22-05-2023 18:00:53

34 Tweet

94 Followers

27 Following

Stanford Department of Medicine (@stanforddeptmed) 's Twitter Profile Photo

From challenges to solutions: #StanDOM's Peter Greenberg & Gabriel Mannis are investigating the stability of myelodysplastic syndromes (#MDS) & effective treatments for acute myeloid leukemia (#AML). stanford.io/3MZeDS7

From challenges to solutions: #StanDOM's Peter Greenberg & Gabriel Mannis are investigating the stability of myelodysplastic syndromes (#MDS) & effective treatments for acute myeloid leukemia (#AML). 
stanford.io/3MZeDS7
Stanford Department of Medicine (@stanforddeptmed) 's Twitter Profile Photo

.Alfonso Molina, MD, MPH is a physician whose passion for medicine was sparked by translating at his family's medical appointments as a child. Now a resident, he combines his expertise in medicine with an understanding of public health. #HispanicHeritageMonth stanford.io/3TVC7M2

.<a href="/AlfonsoMolinaMD/">Alfonso Molina, MD, MPH</a> is a physician whose passion for medicine was sparked by translating at his family's medical appointments as a child. Now a resident, he combines his expertise in medicine with an understanding of public health. #HispanicHeritageMonth stanford.io/3TVC7M2
Stanford Department of Medicine (@stanforddeptmed) 's Twitter Profile Photo

Exciting updates in our Fall 2024 Stanford Hematology Division Newsletter! Welcome Dalia VanderZee as our new Admin Division Director, plus achievements from Drs. Bhatt & Ravi Majeti! 🎉 Read more: bit.ly/3YuuVcc

Mullally Lab (@mullallylab) 's Twitter Profile Photo

Looking forward to welcoming Dr. Wendy Stock to Stanford Hematology Division this week. Recent FDA approval of #blinatumomab as consolidation for #acutelymphoblasticleukemia is one of many exciting developments, excited to hear Dr. Stock’s presentation! Stanford Department of Medicine

Looking forward to welcoming Dr. Wendy Stock to <a href="/StanfordHeme/">Stanford Hematology Division</a> this week.
Recent FDA approval of #blinatumomab as consolidation for #acutelymphoblasticleukemia is one of many exciting developments, excited to hear Dr. Stock’s presentation! <a href="/StanfordDeptMed/">Stanford Department of Medicine</a>
Mullally Lab (@mullallylab) 's Twitter Profile Photo

A big Stanford Hematology Division shout out to Dr. Gabe Mannis who led this study for our group, we are proud to have contributed to this effort! @stanfordcancer Stanford Department of Medicine FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation fda.gov/drugs/resource…

Stanford Medicine (@stanfordmed) 's Twitter Profile Photo

Stanford Medicine's Giselle Salmasi, MD, in collaboration with a Mayo Clinic colleague, has given new hope to a patient diagnosed with a newly identified blood-clotting disorder. scopeblog.stanford.edu/2024/11/22/blo…

Stanford Hematology Division (@stanfordheme) 's Twitter Profile Photo

🚨 Exciting Opportunity Stanford Hematology Division 🚨 We are hiring a Classical Hematologist! Join our dynamic team dedicated to advancing hematology through exceptional teaching, research, and clinical care. Learn more & apply: jobcenter.hematology.org/job/14467 Stanford Medicine Stanford Department of Medicine

Mullally Lab (@mullallylab) 's Twitter Profile Photo

Congrats to all on this paper, phase 1 study now open Stanford Hematology Division ⁦⁦Stanford Department of Medicine⁩ Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN | Blood | American Society of Hematology ashpublications.org/blood/article/…

Stanford Medicine (@stanfordmed) 's Twitter Profile Photo

The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed with a rare cardiovascular disease, transthyretin amyloid cardiomyopathy, or ATTR-CM. stan.md/3CNVrF1

The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed with a rare cardiovascular disease, transthyretin amyloid cardiomyopathy, or ATTR-CM.  stan.md/3CNVrF1
Stanford Hematology Division (@stanfordheme) 's Twitter Profile Photo

Excited to share our team's latest research at #ASH24 ! Check out our abstracts on innovative therapies and breakthroughs in hematology! 🩸 Stanford Hematology Division ASH sway.cloud.microsoft/nCNvDxQg5tm7V5…

Stanford Hematology Division (@stanfordheme) 's Twitter Profile Photo

✨Exciting Opportunity✨ Stanford Hematology Division is looking to enhance our scientific portfolio by bringing a lab-based physician scientist. For more information about the position, including required qualifications and application materials, please visit: tinyurl.com/4bdh83t8

Amer Zeidan MBBS,MHS ‏عامر زيدان (@dr_amerzeidan) 's Twitter Profile Photo

A true pleasure to visit Stanford University to give a Breakthroughs in Hematology talk & chat with #MDSsm legend Dr Peter Greenberg, Drs William Shomai & Ben Rolles, & Dr Ravi Majeti Majeti Lab, Dr Jason Gottlieb, & Dr Ann Mullally Mullally Lab. Thanks for kind hospitality Yale Cancer Center

A true pleasure to visit <a href="/Stanford/">Stanford University</a> to give a Breakthroughs in Hematology talk &amp; chat with #MDSsm legend Dr Peter Greenberg, Drs William Shomai &amp; Ben Rolles, &amp; Dr Ravi Majeti <a href="/majetilab/">Majeti Lab</a>, Dr Jason Gottlieb, &amp; Dr Ann Mullally <a href="/MullallyLab/">Mullally Lab</a>. Thanks for kind hospitality <a href="/YaleCancer/">Yale Cancer Center</a>